Literature DB >> 8841439

Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays.

E C Hagen1, K Andrassy, E Csernok, M R Daha, G Gaskin, W L Gross, B Hansen, Z Heigl, J Hermans, D Jayne, C G Kallenberg, P Lesavre, C M Lockwood, J Lüdemann, F Mascart-Lemone, E Mirapeix, C D Pusey, N Rasmussen, R A Sinico, A Tzioufas, J Wieslander, A Wiik, F J Van der Woude.   

Abstract

Anti-neutrophil cytoplasmic antibodies (ANCA) are diagnostic markers for systemic vasculitis. They are classically detected by an indirect immunofluorescence test using normal donor neutrophils as substrate. This assay lacks antigenic specificity and is not quantitative. The 'EC/BCR Project for ANCA Assay Standardization' is an international collaboration study with the aim to develop and standardize solid phase assays for ANCA detection. In this part of the study the isolation and characterization of proteinase-3 and myeloperoxidase, the two main target molecules for ANCA, and the development and standardization of ELISAs with these antigens are described. Six laboratories successfully isolated purified proteinase-3 preparations that could be used. Three of these preparations, together with one myeloperoxidase preparation, were subsequently used for ANCA testing by ELISA. The ELISA technique was standardized in two rounds of testing in the 14 participating laboratories. The coefficient of variation of these new assays decreased from values of approx. 50% in the first round to approx. 20% in the second round. We conclude that purified proteinase-3 and myeloperoxidase can be used in standardized ELISAs for ANCA detection. Whether such procedures offer advantages over the IIF test will be determined in a prospective clinical study.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8841439     DOI: 10.1016/0022-1759(96)00111-1

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  18 in total

Review 1.  Clinical value of antineutrophil cytoplasmic antibodies.

Authors:  V Rus; B S Handwerger
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 2.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

Review 3.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

Review 4.  Clinical management and treatment of vasculitis.

Authors:  D Jayne
Journal:  Springer Semin Immunopathol       Date:  2001

5.  Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome.

Authors:  M G Danieli; M Cappelli; G Malcangi; F Logullo; A Salvi; G Danieli
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

6.  Characterization of monoclonal antibodies to proteinase 3 (PR3) as candidate tools for epitope mapping of human anti-PR3 autoantibodies.

Authors:  Y M Van Der Geld; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

7.  Use of immunofluorescence and confocal laser scanning microscopy in identifying rare cases of anti-neutrophil cytoplasmic antibodies (ANCA) showing dual specificities to myeloperoxidase and proteinase3.

Authors:  S S Badakere; Vandana D Pradhan; A F Almeida; Aruna R Pawar
Journal:  J Fluoresc       Date:  2004-07       Impact factor: 2.217

Review 8.  Pulmonary vasculitis.

Authors:  A Burns
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

Review 9.  Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much?

Authors:  J H M Beimler; K Andrassy
Journal:  Pediatr Nephrol       Date:  2004-07-15       Impact factor: 3.714

10.  ANCA-Positive Patients: The Influence of PR3 and MPO Antibodies on Survival Rate and The Association with Clinical and Laboratory Characteristics.

Authors:  J C Drooger; A Dees; A J G Swaak
Journal:  Open Rheumatol J       Date:  2009-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.